TreatSMA

UpLift EMPOWER Marketing with Martyn Sibley from Purple Goat Agency

Published:

Updated:

Tonight Pathfinders are hosting UpLift EMPOWER Marketing with Martyn Sibley from Purple Goat Agency – an event you don’t want to miss! Limited spaces for young people with a muscle weakening condition.

šŸ“† Tuesday 7th November 2023
āŒš 18:00 – 19:00
šŸ“ Online Webinar
šŸ’· FREE
šŸ“ Sign up – https://UpLiftEMPOWER.eventbrite.co.uk

Are you aged 18-30?

Join us for our 4th EMPOWER session on Tuesday at 6 pm. Put your questions to Martyn Sibley, an adult with SMA with a marketing background – if you’ve an interest in marketing, blogging, social media, influencing, media, tourism, representation or just a chance to ask an older adult questions then this is theĀ eventĀ forĀ you!

Latest Posts

  • Calling on all the community to ACT NOW to avoid losing treatments!

    Calling on all the community to ACT NOW to avoid losing treatments!

    Currently, there are two approved treatments for SMA: risdiplam and nusinersen. These treatments were initially approved temporarily under Managed Access Agreements while the NHS and NICE gathered data to assess their cost-effectiveness. Now, as these agreements come to an end, both treatments face a crucial review.

    Read more

  • NICEā€™s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    NICEā€™s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    SMA UK are proud to join together with Treat SMA and MDUK to bring you this webinar about NICEā€™s upcoming Multi Technology Assessment for Spinraza and Risdiplam. 2024 sees the end of the managed access agreements (MAAs) for the two treatments. An expert committee will gather to assess the new clinical and real-world evidence, along…

    Read more

  • Let the battle begin

    Let the battle begin

    This year the Managed Access Agreement for Spinraza and Risdiplam expires. The MAA was put in place five years ago so the pharmaceutical companies could gather more evidence to resubmit to NICE for approval on the NHS with Biogen extending their MAA by a year.

    Read more